| Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ... Journal of the National Cancer Institute 104 (3), 228-239, 2012 | 605 | 2012 |
| Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ... Cancer Cell 31 (6), 833-843. e5, 2017 | 507 | 2017 |
| A multiprotein supercomplex controlling oncogenic signalling in lymphoma JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ... Nature 560 (7718), 387-391, 2018 | 409 | 2018 |
| Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro Q Zhang, CZ Chen, M Swaroop, M Xu, L Wang, J Lee, AQ Wang, ... Cell discovery 6 (1), 80, 2020 | 242 | 2020 |
| Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ... Science translational medicine 11 (519), eaaw0064, 2019 | 186 | 2019 |
| Small molecule compounds targeting miRNAs for cancer therapy PC Monroig, L Chen, S Zhang, GA Calin Advanced drug delivery reviews 81, 104-116, 2015 | 175 | 2015 |
| Targeting microRNAs with small molecules: from dream to reality S Zhang, L Chen, EJ Jung, GA Calin Clinical Pharmacology & Therapeutics 87 (6), 754-758, 2010 | 160 | 2010 |
| Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ... Cancer Cell 39 (4), 566-579. e7, 2021 | 153 | 2021 |
| Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 T Bobrowski, L Chen, RT Eastman, Z Itkin, P Shinn, CZ Chen, H Guo, ... Molecular Therapy 29 (2), 873-885, 2021 | 129* | 2021 |
| From laptop to benchtop to bedside: structure-based drug design on protein targets L Chen, J K Morrow, H T Tran, S S Phatak, L Du-Cuny, S Zhang Current pharmaceutical design 18 (9), 1217-1239, 2012 | 118 | 2012 |
| A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells Y Chen, CA Tristan, L Chen, VM Jovanovic, C Malley, PH Chu, S Ryu, ... Nature Methods 18 (5), 528-541, 2021 | 109 | 2021 |
| Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma Y Fu, DJ Urban, RR Nani, YF Zhang, N Li, H Fu, H Shah, AP Gorka, ... Hepatology 70 (2), 563-576, 2019 | 96 | 2019 |
| An OpenData portal to share COVID-19 drug repurposing data in real time KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ... bioRxiv, 2020 | 85* | 2020 |
| Novel insights of structure-based modeling for RNA-targeted drug discovery L Chen, GA Calin, S Zhang Journal of chemical information and modeling 52 (10), 2741-2753, 2012 | 71 | 2012 |
| A critical assessment of combined ligand-and structure-based approaches to HERG channel blocker modeling L Du-Cuny, L Chen, S Zhang Journal of chemical information and modeling 51 (11), 2948-2960, 2011 | 65 | 2011 |
| Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ... Clinical Cancer Research 23 (23), 7301-7311, 2017 | 62 | 2017 |
| SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors U Jo, Y Murai, S Chakka, L Chen, K Cheng, J Murai, LK Saha, ... Proceedings of the National Academy of Sciences 118 (6), e2015654118, 2021 | 58 | 2021 |
| Overcoming acquired epigenetic resistance to BTK inhibitors AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ... Blood Cancer Discovery 2 (6), 630-647, 2021 | 48 | 2021 |
| Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs I Vannini, PM Wise, KB Challagundla, M Plousiou, M Raffini, E Bandini, ... Nature communications 8 (1), 1801, 2017 | 46 | 2017 |
| Recent development of anticancer therapeutics targeting Akt J K Morrow, L Du-Cuny, L Chen, E J Meuillet, E A Mash, G Powis, ... Recent patents on anti-cancer drug discovery 6 (1), 146-159, 2011 | 41 | 2011 |
Shuxing ZhangUniversity of Hawaii Cancer CenterBestätigte E-Mail-Adresse bei hawaii.edu